Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis. In this study, PCR mediated automated DNA sequencing is used to check the prevalence of PZA resistance among treatment failure cases of pulmonary tuberculosis. Out of 50 clinical isolates examined, 39 had mutations in the pncA gene that encodes Pyrazinamidase, an enzyme required to activate PZA. Of these, 31 (79.5%) were localized to three regions of pncA. We found two isolates with hitherto unreported mutation at amino acid 26 (Ala-->Gly) of pncA.
Muthaiah
Muthuraj
M
State TB Training and Demonstration Centre, Govt. Hospital for Chest Diseases, Puducherry, India.
Jagadeesan
Sridharan
S
Ayalusamy
Nisha
N
Sreenivasan
Manupriya
M
Prabhu
Sambamurthy Sangamesvara
SS
Muthuraj
Usharani
U
Senthilkumar
Kamatchiyammal
K
Veerappan
Saroja
S
D000581:Amidohydrolases / Q000235:genetics / Q000378:metabolism; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D006801:Humans; D007194:India / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D011718:Pyrazinamide / Q000494:pharmacology* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; D000581:Amidohydrolases; C022490:pyrazinamide deamidase